Analysts think SLS stock price could increase by 302%
Feb 19, 2025, 12:25 PM
-4.33%
What does SLS do
SELLAS Life Sciences Group, a clinical stage biopharmaceutical company based in New York, develops immunotherapeutics for cancer, including galinpepimut-S and SLS009. The company went public in 2008 and employs 16 staff.
3 analysts think SLS stock price will increase by 301.57%. The current median analyst target is $5.10 compared to a current stock price of $1.27. The lowest analysts target is $4.04 and the highest analyst target is $6.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
